Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > IV OV+ICI sequential administration in clinical trials

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Oct 28, 2022 12:58pm

157 Views

Post# 35056237

RE:RE: IV OV+ICI sequential administration in clinical trials

I always thought and hoped that maybe onc would have success with a 2 pronged approach by intravenous and direct injection at the same time along with a CI and chemo combo. They used direct injection many years ago and even with the science progessing would never hurt to try this combo.

<< Previous

Bullboard Posts

Next >>

Thematic Insights report: The Hard Asset Century